Prediction and Evaluation of RR10 Anticancer peptide activity on Ovarian Cancer cells

Abstract

Ovarian cancer remains a formidable challenge in oncology, necessitating the exploration of novel therapeutic strategies with improved efficacy and reduced toxicity. Peptide-based therapies have emerged as promising candidates, offering targeted approaches that leverage specific interactions with molecular targets involved in cancer progression. The RR10 peptide, characterized by its amphipathic structure and validated non-toxic profile, has garnered significant interest for its potential in ovarian cancer treatment. Structural analyses reveal RR10's ability to interact with cell membranes, facilitating targeted delivery and intracellular activity. Bioactivity predictions underscore its potential to modulate critical pathways, with PeptideRanker assigning a high bioactivity score indicative of significant biological effects. Docking studies demonstrate a strong binding affinity between RR10 and the p53 receptor, implicating its role in activating tumor-suppressive pathways crucial for inhibiting ovarian cancer growth. Mechanistic insights suggest RR10 may induce apoptosis and cell cycle arrest, offering a targeted therapeutic approach. Preclinical validation and combination therapies further support RR10's efficacy, paving the way for clinical trials aimed at evaluating its safety and efficacy in ovarian cancer patients. The biotechnological applications of RR10, including drug delivery systems and diagnostic tools, highlight its versatility and potential impact in cancer therapy. This abstract summarizes the multifaceted attributes of RR10, positioning it as a promising candidate for advancing precision medicine in ovarian cancer treatment.